TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 CASK
Heritage Distilling
-- 3.020 
NEWS
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Seres seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Seres seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment